EGFR and non-small cell lung carcinoma: To date, stage IB-IIIA resected NSCLC with EGFR exon 19 deletions or exon 21 p.(L858R) mutation can benefit from adjuvant treatment with osimertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI).